Ultragenyx Pharma (RARE) Tops Q3 EPS by 33c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Join SI Premium – FREE
Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($1.08), $0.33 better than the analyst estimate of ($1.41). Revenue for the quarter came in at $81.6 million versus the consensus estimate of $81.55 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercose ISI downgrades Reddit, says monetization may not offset traffic weakness
- Qualcomm shares fall on Intel warning and legal concerns
- Oxford Square Capital Corp. (OXSQ) Misses Q3 EPS by 1c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
